Compare BNED & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNED | GLSI |
|---|---|---|
| Founded | 1965 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.0M | 327.2M |
| IPO Year | 2015 | 2020 |
| Metric | BNED | GLSI |
|---|---|---|
| Price | $9.00 | $27.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 224.7K | 116.6K |
| Earning Date | 03-10-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $1,610,170,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.90 | $7.78 |
| 52 Week High | $12.19 | $34.10 |
| Indicator | BNED | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 61.75 |
| Support Level | $8.90 | $21.21 |
| Resistance Level | $9.53 | $30.08 |
| Average True Range (ATR) | 0.49 | 1.76 |
| MACD | -0.19 | 0.49 |
| Stochastic Oscillator | 8.06 | 81.15 |
Barnes & Noble Education Inc is a contract operator of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States. The company is also a textbook wholesaler and inventory management hardware and software provider. It offers course materials through physical and online bookstores, including new and used print textbooks, rental options, digital textbooks, and publisher-hosted digital courseware. Products are also offered directly to students through Textbooks.com. The majority of the company's revenue is derived from the sale of products through its bookstore locations, including virtual bookstores, and the bookstore affiliated e-commerce websites.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.